Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al
- PMID: 32591359
- DOI: 10.1136/annrheumdis-2020-218148
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al
Keywords: antirheumatic agents; biological therapy; rituximab.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.Ann Rheum Dis. 2021 May;80(5):e67. doi: 10.1136/annrheumdis-2020-218075. Epub 2020 Jun 26. Ann Rheum Dis. 2021. PMID: 32591357 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical